UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

The New England journal of medicine, 2012-09, Vol.367 (13), p.1187-1197

2012

Volltextzugriff (PDF)

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

The lancet oncology, 2014-09, Vol.15 (10), p.1147-1156

2014

Volltextzugriff (PDF)

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study

The lancet oncology, 2014-05, Vol.15 (6), p.592-600

2014

Volltextzugriff (PDF)

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

European urology, 2018-07, Vol.74 (1), p.37-45

2018

Volltextzugriff (PDF)

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

Journal of clinical oncology, 2018-02, Vol.36 (6), p.572-580

2018

Volltextzugriff (PDF)

An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS680-TPS680

2019

Volltextzugriff (PDF)

Enzalutamide in castration‐resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial

Cancer, 2017-01, Vol.123 (2), p.253-262

2017

Volltextzugriff (PDF)

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

The Lancet (British edition), 2010-04, Vol.375 (9724), p.1437-1446

2010

Volltextzugriff (PDF)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

Cancer, 2017-06, Vol.123 (12), p.2303-2311

2017

Volltextzugriff (PDF)

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results

The Journal of urology, 2018-02, Vol.199 (2), p.459-464

2018

Volltextzugriff (PDF)

Development of enzalutamide for metastatic castration-resistant prostate cancer

Annals of the New York Academy of Sciences, 2015-11, Vol.1358 (1), p.13-27

2015

Volltextzugriff (PDF)

Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial

European urology, 2015-02, Vol.67 (2), p.223-230

2015

Volltextzugriff (PDF)

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results

European urology, 2015-11, Vol.68 (5), p.787-794

2015

Volltextzugriff (PDF)

Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.165-165

2017

Volltextzugriff (PDF)

Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5035-5035

2015

Volltextzugriff (PDF)

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5062-5062

2016

Volltextzugriff (PDF)

Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5007-5007

2017

Volltextzugriff (PDF)

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.266-266

2016

Volltextzugriff (PDF)

Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.220-220

2017

Volltextzugriff (PDF)

Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.5065-5065

2013

Volltextzugriff (PDF)

Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America

The Prostate, 2015-06, Vol.75 (8), p.836-844

2015

Volltextzugriff (PDF)

PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS5094-TPS5094

2014

Volltextzugriff (PDF)

Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.20-20

2013

Volltextzugriff (PDF)

Enzalutamide in European and North American men participating in the AFFIRM trial

BJU international, 2015-01, Vol.115 (1), p.41-49

2015

Volltextzugriff (PDF)

Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5068-5068

2014

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(36)
Buchkapitel
(1)

Sprache

Englisch
(37)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma

Enzalutamide in castration‐resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results

Development of enzalutamide for metastatic castration-resistant prostate cancer

Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results

Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study

Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study)

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM

Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM

Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results

Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America

PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients

Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes

Enzalutamide in European and North American men participating in the AFFIRM trial

Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients

Suchergebnisse filtern